SCHEMBL24974747

SCHEMBL24974747

CCCOCCOCCOCCn1cc(-c2cnc(N3CC(C(=O)N4CCC5(CC4)NC(=O)N(Cc4ccccc4)C5=O)C3)nc2)nn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK3 O43781 1/20 0.36
▸ ROCK2 O75116 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ CLK2 P49760 1/20 0.36
▸ GSK3A P49840 1/20 0.36
▸ GSK3B P49841 1/20 0.36
▸ CSNK1G2 P78368 1/20 0.36
▸ PRKG1 Q13976 1/20 0.36
▸ CLK4 Q9HAZ1 1/20 0.36
▸ SGK2 Q9HBY8 1/20 0.36
▸ CSNK1G1 Q9HCP0 1/20 0.36
▸ CSNK1G3 Q9Y6M4 1/20 0.36
▸ TACR1 P25103 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ FABP7 O15540 1/20 0.34
▸ BCHE P06276 2/20 0.33
▸ ABCG2 Q9UNQ0 4/20 0.33
▸ HCRTR1 O43613 1/20 0.33
▸ HCRTR2 O43614 1/20 0.33
▸ EGLN1 Q9GZT9 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21150836 0.89 DYRK3 (0.33) DYRK3ROCK2MAPK1CLK2GSK3A
SCHEMBL24974591 0.82 TACR1 (0.40) DYRK3ROCK2MAPK1CLK2GSK3A
SCHEMBL24974727 0.76 KMT2A (0.40) DYRK3ROCK2MAPK1CLK2GSK3A
SCHEMBL21151320 0.76 TACR1 (0.37) DYRK3ROCK2MAPK1CLK2GSK3A
SCHEMBL21151896 0.75 KMT2A (0.46) TACR1KMT2AKDM4EALDH1A1
SCHEMBL24974686 0.74 TACR1 (0.35) DYRK3ROCK2MAPK1CLK2GSK3A
SCHEMBL24974746 0.74 NPY5R (0.37) FABP7EGLN1
SCHEMBL24974605 0.74 TACR1 (0.49) DYRK3ROCK2MAPK1CLK2GSK3A
SCHEMBL24974594 0.74 KMT2A (0.41) DYRK3ROCK2MAPK1CLK2GSK3A
SCHEMBL24974734 0.72 NAMPT (0.54) DYRK3ROCK2MAPK1CLK2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572370-B2 CD16A binding agents and uses thereof BIOHAVEN THERAPEUTICS LTD. (US) 2023-02-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572370-B2 CD16A binding agents and uses thereof FCGR1A, FCGR2A, FCGR3B DYRK3 3386/4885ROCK2 1950/4885MAPK1 3778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback